Epidemiology of biliary tract cancer in China: A narrative review

被引：0

作者：

Zhou, Jun ^{[1
]}

Tan, Guang ^{[2
]}

Zhang, Lei ^{[3
]}

Xie, Ganfeng ^{[5
]}

Chen, Wenting ^{[6
]}

Zhang, Xijie ^{[6
]}

Liang, Houjie ^{[4
,5
]}

机构：

[1] Peking Univ, Minist Educ Beijing, Dept Gastrointestinal Oncol, Key Lab Carcinogenesis & Translat Res,Canc Hosp In, Beijing 100142, Peoples R China

[2] Dalian Med Univ, Affiliated Hosp 1, Dept Gen Surg, Dalian 116011, Peoples R China

[3] Sun Yat sen Univ, Sun Yat sen Mem Hosp, Dept Hepatobiliary Surg, Guangzhou 116011, Peoples R China

[4] Third Mil Med Univ, Army Med Univ, Southwest Hosp, Dept Oncol, Chongqing 400038, Peoples R China

[5] Third Mil Med Univ, Army Med Univ, Southwest Hosp, Southwest Canc Ctr, Chongqing 400038, Peoples R China

[6] MSD China, Value & Implementat, Global Med & Sci Affairs, Shanghai 200233, Peoples R China

来源：

CHINESE JOURNAL OF CANCER RESEARCH | 2024年 / 36卷 / 05期

关键词：

Biliary tract cancer; China; epidemiologic methods; review; INTRAHEPATIC CHOLANGIOCARCINOMA; CONSENSUS STATEMENT; METABOLIC SYNDROME; PROGNOSTIC-FACTORS; RISK-FACTORS; RECURRENCE; SHANGHAI; CARCINOMA; RESECTION; PATTERNS;

D O I：

10.21147/j.issn.1000-9604.2024.05.02

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Biliary tract cancer (BTC) is a group of rare malignancies that affect the gallbladder and bile ducts. Although rare, BTC is becoming a significant public health burden in China, particularly among males and older individuals. The increasing trends in BTC incidence and mortality in China are influenced by various demographic, environmental, and lifestyle factors. In this review, we examine available epidemiological data on the incidence, mortality, prognosis, and trends of different BTC subtypes in China. We also discuss the challenges and opportunities for improving the prevention, diagnosis, and management of BTC in China, and identify areas for further research and intervention. The article aims to provide a better understanding of the epidemiological features of BTC in China and to inform public health strategies and clinical practice.

引用

页数：17

共 50 条

[41] A Perspective on Cell Therapy and Cancer Vaccine in Biliary Tract Cancers (BTCs)
Han, Shuting
Lee, Suat Ying
Wang, Who-Whong
Tan, Yu Bin
Sim, Rachel Hui Zhen
Cheong, Rachael
Tan, Cherlyn
Hopkins, Richard
Connolly, John
Shuen, Wai Ho
Toh, Han Chong
CANCERS, 2020, 12 (11) : 1 - 15
[42] Cisplatin/gemcitabine or oxaliplatin/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review
Fiteni, Frederic
Nguyen, Thierry
Vernerey, Dewi
Paillard, Marie-Justine
Kim, Stefano
Demarchi, Martin
Fein, Francine
Borg, Christophe
Bonnetain, Franck
Pivot, Xavier
CANCER MEDICINE, 2014, 3 (06): : 1502 - 1511
[43] Patterns of Initial Disease Recurrence after Resection of Biliary Tract Cancer
Jung, Se Jin
Woo, Sang Myung
Park, Hyung Ki
Lee, Woo Jin
Han, Mi Ah
Han, Sung-Sik
Kim, Seong Hoon
Park, Sang-Jae
Kim, Tae Hyun
Koh, Young Hwan
Hong, Eun Kyung
ONCOLOGY, 2012, 83 (02) : 83 - 90
[44] Surgical Resection for Pulmonary Metastasis from Pancreatic and Biliary Tract Cancer
Tagawa, Tetsuzo
Ito, Kensaku
Fukuzawa, Kengo
Okamoto, Tatsuro
Yoshimura, Atsuro
Kawasaki, Takahide
Masuda, Takashi
Iwaki, Kentaro
Terashi, Takahiro
Okamoto, Masahiro
Shiromizu, Akio
Motohiro, Akira
Maehara, Yoshihiko
ANTICANCER RESEARCH, 2017, 37 (03) : 1413 - 1416
[45] Risk estimation for biliary tract cancer: Development and validation of a prognostic score
Schweitzer, Nora
Fischer, Mareike
Kirstein, Martha M.
Berhane, Sarah
Kottas, Martina
Sinn, Marianne
Gonzalez-Carmona, Maria A.
Balta, Zeynep
Weismueller, Tobias J.
Strassburg, Christian P.
Reineke-Plaass, Tanja
Bektas, Hueseyin
Manns, Michael P.
Johnson, Philip
Weinmann, Arndt
Vogel, Arndt
LIVER INTERNATIONAL, 2017, 37 (12) : 1852 - 1860
[46] Clinical outcomes of salvage chemoradiotherapy for locally recurrent biliary tract cancer
Yu, Jeong Il
Park, Hee Chul
Lim, Do Hoon
Park, Joon Oh
Park, Young Suk
Kim, Seung Tae
Choi, Seong Ho
Choi, Dong Wook
Han, In Woong
Heo, Jin Seok
TUMORI JOURNAL, 2017, 103 (04): : 345 - 352
[47] Efficacy and Safety of Gemcitabine Monotherapy for Patients with Advanced Biliary Tract Cancer
Yokoyama, Tadashi
Yoshida, Hiroshi
Makino, Hiroshi
Maruyama, Hiroshi
Suzuki, Seiji
Matsutani, Takeshi
Matsushita, Akira
Hirakata, Atsushi
Sasajima, Koji
Uchida, Eiji
JOURNAL OF NIPPON MEDICAL SCHOOL, 2012, 79 (03) : 204 - 212
[48] Role of chemotherapy in treatments for biliary tract cancer
Furuse, Junji
Kasuga, Akiyoshi
Takasu, Atsuko
Kitamura, Hiroshi
Nagashima, Fumio
JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, 2012, 19 (04) : 337 - 341
[49] Editorial: Novel therapeutic approaches for biliary tract cancer and hepatocellular carcinoma
Bekric, Dino
Tornesello, Maria Lina
Ocker, Matthias
Mayr, Christian
Kiesslich, Tobias
Neureiter, Daniel
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2023, 11
[50] Association of tea and coffee consumption and biliary tract cancer risk: The Biliary Tract Cancers Pooling Project
Huang, Yu-Han
Loftfield, Erikka
Argirion, Ilona
Adami, Hans-Olov
Albanes, Demetrius
Chan, Andrew T.
Fedirko, Veronika
Fraser, Gary E.
Freedman, Neal D.
Giles, Graham G.
Hartge, Patricia
Katzke, Verena
Knutsen, Synnove F.
Lacey, James
Liao, Linda M.
Luo, Juhua
Milne, Roger L.
O'Brien, Katie M.
Peters, Ulrike
Poynter, Jenny N.
Purdue, Mark P.
Robien, Kim
Sandin, Sven
Sandler, Dale P.
Setiawan, Veronica W.
Kang, Jae H.
Simon, Tracey G.
Sinha, Rashmi
Vopham, Trang
Weinstein, Stephanie J.
White, Emily
Zhang, Xuehong
Mcglynn, Katherine A.
Campbell, Peter T.
Lee, Mei-Hsuan
Koshiol, Jill
HEPATOLOGY, 2024, 79 (06) : 1324 - 1336

← 1 2 3 4 5 →